Abstract Parvovirus H-1 (H-1 PV) preferentially replicates in malignant cells resulting in their death by cytolysis. It has often been considered a potential candidate for use in novel anticancer therapy. To evaluate its potential in a model of natural tumors, we assayed in vitro the effect exerted by H-1 PV on short-term cultures derived from breast tumor samples freshly excised from patients. Our results show that H-1 PV effectively kills tumor-derived cells, whereas normal tissue-derived cells showed no H-1 PV-induced cytopathic effects (CPE). We also determined that the H-1 PV sensitivity (up to 67% sensitive cultures) is related with the quantities of virus assayed. We further examined the expression and phosphorylation state of the parvoviral nonstructural protein 1 (NS1), known to be associated with parvoviruses-induced CPE. Both appear to be impaired in normal tissue-derived cells and resistant cultures. Finally, we show that H-1 PV sensitivity in cultures correlates significantly with higher tumor grades (Nottingham combined histologic grade 2 or 3). This report confirms that H-1 PV can efficiently induce CPE in primary breast tumor cells in vitro. It identifies tumor characteristics representing potential criteria for recruiting patients for clinical evaluation of H-1 PV antitumor effects.
Introduction
Developing cancer-eradicating agents with low toxicity remains a prime goal. An attractive prospect is the use of oncolytic viruses, i.e., natural agents that act like tumorcell parasites and are able to find and destroy malignant cells selectively [1] . Many different viruses of several viral families, such as Herpes simplex virus [2, 3] , Reovirus [4] , Adenovirus [5] , and Parvovirus [6, 7] , possess such properties. Those associated with limited or no toxicity are relevant to potential clinical use.
The rodent autonomous oncolytic parvovirus H-1 (H-1 PV) is a small (*25 nm), nonenveloped virus with singlestranded DNA (*5 kb). It replicates efficiently in human tumor cells in an episomal fashion, yielding infectious viral progeny. H-1 PV has never been linked to any pathology in humans [8] . Even retrospectively, no correlation has been found between H-1 PV serological detection and any pathology [9] . When H. Toolan (in 1965) injected the virus into two patients (12 and 13 years old) severely affected by osteosarcomas that had metastasized, with no other therapeutic option left, the virus caused no detectable side effect [10] . Ultimately, nevertheless, only a proper phase-I clinical trial with H-1 PV will be able to establish its therapeutic interest and innocuousness.
H-1 PV-induced destruction of malignant human cells has often been reported, both in vitro (transformed cell lines) and in vivo (human cell lines xenografted in animal models) [11, 12] . As demonstrated with the closely related Minute Virus of Mice (MVM), the cytopathic effects (CPE) exerted on malignant cells result from expression of the parvoviral nonstructural protein 1 (NS1) [13, 14] , its phosphorylation [15] , and its interaction with cell proteins, resulting in cytoskeletal modifications and cell death [16] .
The tropism of H-1 PV for neoplastic cells has also been dissected in many studies. The virus can enter both normal and transformed cells. In the former, it seems only to cause abortive infection without proper neovirion production [14] . In the latter, a complete viral cycle can occur leading to release of new virions upon host cell lysis. Fibroblasts transformed by ionizing radiation, a chemical carcinogen, or a tumor virus [17] and spontaneously or tumor virustransformed keratinocytes [18] appear much more sensitive to H-1 PV-induced cell killing than their normal parental counterparts. The greater H-1 PV permissiveness of transformed cells might be attributable to changes in the nature and quantity of cell factors associated with cell cycling [19] . Activation of cell division might not suffice, since the differentiation status of the cell also appears to play a role in correct replication of H-1 PV [14] . Cell immortalization, resulting in permanent cell proliferation (a high proportion cells in the S phase), plus cell transformation thus represent ideal conditions for efficient parvovirus replication.
Most information concerning effective killing of malignant cells by H-1 PV has been obtained in studies on cell lines. Despite their overall relevance thanks to repeated observations, this information pertains model systems where conditions differ considerably from the physiopathological reality encountered in patients' tumor tissues. Only two preliminary studies have described H-1 PVinduced cell killing in primary breast tumor cells [20, 21] . The authors have notably demonstrated cytopathic effect induced by H-1 PV preferentially in tumor cells, as opposed to normal cells derived from the same patients [20] .
In this study, we examine a large number of short-term breast tumor-derived cultures in order (1) to quantify precisely the H-1 PV-induced cell killing, (2) to test if there is a H-1 PV dose-effect, (3) to analyze the viral cytotoxic protein NS1 expression, (4) to determine if tumors' histopathological characteristics are predictive of H-1 PVinduced cell killing.
Materials and methods
All products were purchased from Invitrogen (Paisley, UK) unless otherwise specified.
HeLa-GFP xenografted-tumor-derived cell cultures and H-1 PV infection SCID-mice (Institut Pasteur de Lille) were grafted with HeLa-GFP cells as described in [12] . After 10 days, tumors (&100 mm 3 ) were detectable. Mice were euthanized (in agreement with the ethical committee of our institution), and the excised tumors were minced as finely possible and disaggregated in a solution of dispase (10 mg/ml) and collagenase (5 mg/ml) at 37°C under gentle stirring for at least 1 h. The enzymatic reaction was stopped by addition of OptiMEM supplemented with 10% FCS. The cells were centrifuged. The pellet was resuspended in DMEM medium supplemented with 10% FCS, L-glutamine (2 mM), gentamycin (8 lg/ml), and neomycine (900 lg/ml) and plated in 100-mm-diameter culture dishes. Once cultures were established, cells were counted and plated in 12-well plates at 20,000 cells/well. The next day, cells were infected with H-1 PV at different multiplicities of infection (MOIs) or mock treated in control wells (Fig. 1a) .
Short-term breast tumor-derived cell cultures and H-1 PV infection
Samples of invasive breast carcinomas (according to the World Health Organization classification) were collected at the Centre Oscar Lambret (Lille, France) in the Pathology Department in agreement with all ethical rules specified by the French Ministry of Research for use of patients' samples for research purposes. All patients were women and agreed for use of their tumor samples in our study. The tumor samples were obtained during surgical resection of newly diagnosed tumors, before any other anticancer treatment (chemotherapy, hormonotherapy, or radiotherapy). Patients' tumor detailed histopathological examination reports, including the Nottingham combined histologic grade (differentiation status, mitotic count, nuclear pleomorphism), vascular and sentinel and/or axillary lymph node invasion status, estrogen and progesterone receptor expression, were collected (see Table 1 ). Upon receipt immediately after surgery, the patients' tumor samples were dissected and analyzed by a pathologist. One part of the sample was transferred to a tube containing OptiMEM medium supplemented with 10% FCS, L-glutamine (2 mM), and gentamycin (8 lg/ml).
Upon arrival, the samples were weighed, decontaminated in Betadine Ò 10% dermal solution (Vitaris Manufacturing, Mérignac, France), and washed twice in PBS and disaggregated as described with HeLa-GFP tumors. Once monocellular suspensions were obtained, breast tumor cells were resuspended in serum-free Mammary Epithelial Cell Growth Medium (PromoCell, Heidelberg, Germany) supplemented with bovine pituitary extract (0.052 mg/ml), epidermal growth factor (10 ng/ml), insulin (5 lg/ml), and hydrocortisone (0.5 lg/ml) (supplied by PromoCell with the medium) and plated in 35-mm-diameter culture dishes.
After one night at 37°C, dead floating cells were eliminated, and live adhering cells were left to proliferate (Fig. 1b-picture 2) . After two to three passages, when sufficient cells were available, the cells were counted and plated in 24-well plates at 25,000 cells/well. The next day, the cells were infected with H-1 PV at different MOIs or mock treated in control wells (Fig. 1b ).
Virus and cell lines
For infection, H-1 PV was produced in a human cell line, as described in [22] , from a plasmid containing the wildtype H-1 PV genome (kindly provided by Pr J. Rommelaere, Heidelberg, Germany). Virus stock titers were determined according to plaque assays published methods [23] . The multiplicity of infection (MOI) is given by number of plaque-forming units (pfu) inoculated per cell.
SK-BR-7 and MDA-MB-231 cells (kindly provided by Dr P. Mehlen, Lyon, France) were cultured, respectively, in RPMI medium supplemented with 10% FCS and gentamycin (8 lg/ml) and DMEM medium supplemented with 10% FCS, L-glutamine (2 mM), and gentamycin (8 lg/ml).
Parvovirus-H-1-induced CPE assay
Seven days postinfection, H-1 PV-induced CPE were observed after Giemsa staining (Fig. 1b, picture 3) . Briefly, the culture medium was removed, the cells were washed twice with physiological water, fixed in methanol for 10 min, stained for 1 h at room temperature with diluted (1/10 in tap water) Giemsa stain modified solution (SigmaAldrich, Steinheim, Germany), and dried after a final wash. The level of cytotoxicity was evaluated by direct microscopic observation, and pictures (representing &70% of the well) were taken. Cultures were considered sensitive to H-1 PV-induced CPE when massive cytolysis ([50% of the cells) was observed when compared to the mock-treated well.
Parvovirus-H-1-induced CPE quantification
The H-1 PV-induced CPE were quantified 7 days postinfection by means of a tetrazolium salt (MTT) viability assay (as described in [24] ) for n = 30 tumor-derived cultures. Each condition was tested in duplicate. Briefly, the medium was removed and replaced with 500 lL of MTT solution (Sigma-Aldrich) diluted (final concentration: 0.5 mg/ml) in Mammary Epithelial Cell Growth Medium, then the culture was incubated for 4 h at 37°C. MTT salts were metabolized to formazan salts by viable cells and released in the supernatant after addition of a solubilization solution and incubation for 1 h at room temperature. A 100-ll volume of supernatant was transferred to a well in a 96-well plate (in duplicate) and read with a microplate spectrophotometer-reader (Multiskan RC, Thermo Labsystems, Helsinki, Finland) at 540 and 620 nm. The background absorbency (at 620 nm) was subtracted from the value obtained at 540 nm. The viability of the infected cells was expressed as the ratio of the corresponding absorbency to that of noninfected cells set arbitrarily at 100%.
Western blot analysis
Forty-eight hours postinfection, before any H-1 PVinduced effect was visible, the cells were lysed in PY buffer [25] supplemented with 0.04% Complete EDTAfree TM Protease Inhibitor Cocktail (Roche, Manheim, Germany). Cell lysates were stored at -20°C. Equal amounts of the various lysates were loaded. After 10% SDS-PAGE separation, the proteins were transferred onto Expression levels were analyzed with a LAS-3000 imaging system (FUJIFILM, Quentin en Yvelines, France).
Statistical analysis
Breast tumor samples (n = 112) were obtained from the Centre Oscar Lambret. Some samples were excluded from the statistical analysis because of bacterial contamination in culture or because of technical difficulties in deriving the cultures. Similarly, a small number of samples of undifferentiated or epidermoid or mucinous breast cancer were also excluded in order to compare homogeneous subgroups. The statistical analysis was thus performed on 96 samples. First, a descriptive analysis (frequencies, boxplot, etc.) was performed in order to check and recapitulate the data. Then, comparisons of subgroups were performed. In accordance with parameter distribution and subgroup size, comparisons of means were performed using the nonparametric Wilcoxon test. Comparisons of frequencies were performed using the Chi-square test or Fisher's exact test if necessary. All analyses were carried out with the SAS software, V9.1. The significance level was set at 0.05.
Results
Parvovirus H-1 induces cytopathic effect on cultures from freshly excised xenografted HeLa-GFP tumors Solid HeLa-GFP tumors were obtained in SCID-mice (Fig. 1a-picture 1) . The advantage of using HeLa carcinoma cells stably expressing GFP enable us to visualize specifically the destruction of malignant cells in vitro when H-1 PV was added (Fig. 1a, control well compared to MOI 1 and MOI 5).
This model experiment is a proof-of-concept of our in vitro assay showing H-1 PV-induced CPE on short-term derived tumor cell cultures. This assay was then subsequently used with patients' tumors as described in the following sections.
Parvovirus H-1 induces cytolysis of short-term breast tumor-derived cells, as opposed to normal cells
To examine H-1 PV-induced CPE on primary breast tumor cells, short-term cultures were derived from breast tumor samples freshly excised from patients (Fig. 1b) . As controls, cultures were also derived from normal peritumoral tissue taken from the same patients (6 samples). To avoid stromal cell contamination in our cultures, we used a media specifically designed for the culture of mammary epithelial cells (confirmed by cytokeratin 19 labeling, data not shown). The tumor types studied were mainly ductal carcinomas (82%) and invasive lobular carcinomas (18%). Eighty-four percent of the samples were from undifferentiated tumors (differentiation grade 3). As for the Nottingham combined histologic grade, most of the samples were from high-grade tumors (51% grade-2 and 39% grade-3 tumors). Detailed histologic data are presented in Table 1 .
Once primary cell cultures were successfully established in a media, they were infected with H-1 PV at varying multiplicity of infection (MOI) and incubated for 1 week, at which time CPE were evaluated. As illustrated in Fig. 2 , cultures derived from an invasive ductal carcinomas (grade 3, ER?, PR?) showed very severe H-1 PVinduced CPE, in contrast to the corresponding normal cell cultures (Fig. 2 rows B and A, respectively) . The latter showed an effect only at the highest dose tested (MOI 100), and even then the effect was weak.
H-1 PV-infected tumor-cell cultures showed a dosedependent reduction in cell number (Fig. 2, rows B: MOI 1, MOI 10 and MOI 100), in contrast to mock-treated tumor-cell cultures (Fig. 2, control) . The level of sensitivity to H-1 PV-induced CPE varied among the different tumor samples examined.
The exploitation of these data was hampered by a major difficulty; patients' tumors are quite heterogeneous by nature, as opposed to tumor cell lines that appear very homogeneous in culture. A more refined and quantitative test was thus required as described in the next section.
Quantification and analysis of the differential effect of H-1 PV on normal and tumor-derived cells
The assay based on spectrophotometric detection of purple formazan produced by the metabolic action on tetrazolium salts (MTT) of mitochondrial dehydrogenases in living cells is commonly used to measure cell death induced by toxic chemicals or biological substances. Here, the MTT viability assay was used to quantify H-1 PV-induced CPE.
To compare the results of this assay with those obtained by Giemsa staining, we first used two breast carcinoma cell lines, the MDA-MB-231 and SK-BR-7. The cells were infected (at MOI 1, 5, or 10 or with no virus in control wells) and incubated for 7 days. Giemsa staining (Fig. 3a) and MTT quantification (Fig. 3b) were done in parallel. The viable cell rates measured by the MTT assay appeared to tally quite accurately with the visual impression after cell staining.
After 1 week H-1 PV appears to affect MDA-MB-231 cells very severely, since cells infected at MOI 1, MOI 5, and MOI 10 showed, respectively, only 10.2 ± 0.8%, 8.7 ± 0.3%, and 9.1 ± 0.8% survival. In control wells, in contrast, survival was 100 ± 5.3%. The effect of H-1 PV on SK-BR-7 cells was almost as drastic, leading to 28 ± 1.7%, 26.7 ± 1.8%, and 9.7 ± 1.66% at MOI 1, 5, and 10, respectively (Fig. 3b) .
The same procedure was used to quantify H-1 PV-induced CPE on cultures derived from fresh normal and tumoral breast tissues (Fig. 4b, A and B, respectively) . The former cultures displayed little or no H-1 PV-induced cell death, with 80 ± 6.5% or 72 ±5.2% of the cells remaining viable 7 days postinfection at MOI 1 or MOI 100, respectively (Fig. 4b, A) . Of the tumor-derived cells, only 69 ± 3% and 28 ± 1% of the cells remained viable 7 days postinfection at MOI 1 or MOI 100, respectively (Fig. 4b, B) . The quantification test appeared as a decisive addition to the visual results obtained by Giemsa staining (Fig. 4a) .
Differential expression and phosphorylation of the NS1 cytotoxic protein in the normal and tumor-derived cells
To further investigate reasons for the differential response to H-1 PV infection in the above-described normal and tumorderived cells, we measured expression of the cytotoxic protein NS1 by immunoblotting with a specific antiserum directed against the carboxy-terminal region of the protein [26] (Fig. 4c) . When expression profiles were compared 48 hours after infection with H-1 PV, cells derived from normal tissue showed much lower levels of both NS1 (lower band) and its active phosphorylated form (NS1-P, upper band) (Fig. 4c, A) than the corresponding tumor-derived cells. More interestingly, the ratio of NS1-P to NS1 was very different in the two situations, the phosphorylated form being more abundant in tumor-derived cells and less abundant in normal cells than unphosphorylated NS1.
Tumor histopathologic characteristics predictive of sensitivity to H-1 PV-induced CPE Of the 96 tumors collected and considered for statistical analysis (see ''Materials and methods''), 69 yielded successful short-term cultures (72%). Among these successfully cultured tumors, 48% yielded cultures sensitive to H-1 PV and 35% yielded resistant cultures. For 17% of the cultures, the level of sensitivity was intermediate. To study the factors predictive of sensitivity toward H-1 PV oncolysis, only the sensitive and resistant groups were compared. Only cultures from high-grade tumors appeared significantly (P = 0.03) sensitive to H-1 PV-induced CPE (Fig. 5) . A trend (P = 0.07) toward higher sensitivity was also associated with a higher mitotic grade (data not shown). Tumor-derived cells sensitivity to H-1 PV increase with higher doses H-1 PV-induced CPE was examined with increasing quantities of virus. On a total number of 79 tumor-derived cultures, 61 were treated with doses of H-1 PV up to MOI 25, 47% were sensitive, 11% showed intermediate sensitivity, and 41% were resistant (Table 2) . On the last 18 tumor-derived cultures assayed, we were able to reach doses up to MOI 100 resulting in 67% of H-1 PV sensitive cultures, 11% intermediately sensitive, and 22% resistant cultures ( Table 2) .
Discussion
Parvovirus H-1 is often referred to as an ideal candidate for use in cancer therapy based on viral agents capable of selectively killing malignant cells [6] . With the Minute Virus of Mice (MVM), H-1 PV is known for its preferential replication in malignant cells (oncotropism) [14, 17] ultimately resulting in their death (oncolysis) [7, 16] . It also appears that H-1 PV injection is not associated with pathological side effects in patients [10] . Breast neoplasia appears as a potential target for H-1 PV-based anticancer virotherapy.
In this study, we have evaluated the in vitro capacity of H-1 PV to destroy primary breast tumor cells. Our data clearly demonstrate that a certain number of short-term cultures derived from freshly excised breast tumors are sensitive to H-1 PV-induced CPE (Figs. 2, 4 , 5, and Table 2 ). H-1 PV exerts its cytotoxic effects in a dosedependent manner: cytolysis is much greater at MOI 10 and MOI 100 than at MOI 1 (Figs. 2, 4) . Most often, to obtain a significant effect, we had to use large quantities of virus (starting at MOI 10 up to MOI 100). This is in contradiction with many studies describing H-1 PV-induced CPE on a variety of cell lines, where low virus doses were sufficient to cause effective cell killing [7, 27] . Our own data show very efficient H-1 PV-induced cytolysis in cultures derived from model HeLa-GFP tumors established in SCID-mice (Fig. 1a) . H-1 PV effect is also massive with MDA-MB-231 and SK-BR-7 cells starting at MOI 1, with almost no viable cells left at MOI 5 and 10 ( Fig. 3) . The use of primary cells might explain this discrepancy, such cells generally cycle less rapidly than cell lines in vitro. It is known that full H-1 PV replication, resulting in final cell killing, strongly depends on cell factors available for efficient cells cycling [28] . In this respect, our statistical analysis applied to the histopathologic characteristics of the tumors from which H-1 PV-sensitive cell cultures were obtained, showed a trend toward a higher number of mitoses in such tumors (P = 0.07). The need for higher quantities of H-1 PV to induce efficient cytolysis in tumorderived cells might also be explained by the fact that viral propagation is limited (as measured for few tumor-derived cultures, data not shown). Although it was shown in [17] that H-1 PV sensitivity does not rely directly on the capacity of propagation of the virus i.e., HT1080 cells with low viral amplification are more severely killed by H-1 PV than KMST-6 cells with higher viral amplification rate. Of the successfully established cultures from breast tumor samples that were assessed in our study, 47% up to 67% were considered sensitive to H-1 PV-induced CPE. A previous study describing H-1 PV-induced CPE on shortterm breast tumor-derived cell cultures (n = 19) established the success rate at 32% [21] . Our better success rate is probably due to the larger quantities of virus we used. When comparing our own data between cultures where H-1 PV doses up to MOI 25 were tested (Table 2 ) with cultures assayed with doses reaching up to MOI 100 we obtained much more higher rate of H-1 PV-induced CPE in the latter case. Thus, this dose effect seems quite relevant, and it was correlated with the levels of expression of NS1, with higher amounts of NS1 at MOI 100 rather than MOI 10 for example (data not shown). If in vitro assays on short-term tumor-derived cell cultures reflect (and predict) the in vivo H-1 PV effects on breast tumors, our results suggest that with high doses of injected H-1 PV, most tumors may be sensitive to its cytotoxic effect.
Yet given the current H-1 PV production capacity, such doses would be difficult to reach in vivo. However, if the virus is to be injected into or close to the tumor, a high number of virus particles per tumor cell could be reached for an average-sized tumor. Multiple injections might likewise be an appropriate way to reach effective doses [29] .
The overall histopathologic characteristics of the tumors analyzed in our study are representative of invasive breast cancer in whole population. We sought to determine whether there was any correlation between sensitivity to H-1 PV-induced CPE and the histopathological subtype of the tumors from which a culture was derived. If so, any observed correlations might provide interesting criteria for the recruitment of patients into a future clinical trial. Van Pachterbeke et al. [21] have shown the presence of estrogen receptors to be a factor predictive of H-1 PV sensitivity. In our study, we found no such correlation. Instead, we found that cultures established from higher tumor grades (Nottingham combined histopathologic grade 2 or 3) show significantly greater sensitivity toward H-1 PV-induced cytolysis (P = 0.03). Such grades indicate that tumoral cells present in these samples are quite undifferentiated. Undifferentiated malignant cells [14] are often assumed to be particularly sensitive to H-1 PV-induced killing, though so far no transcription factor or growth factor or any other molecular element associated with the cell differentiation status has clearly surfaced.
NS1, a key multifunctional parvoviral protein, is particularly important in initiating replication of the viral genome [30] and producing new virions [31] . It is also critically involved in the cytotoxicity caused by the virus [15, 16] . Our data confirm this involvement, as we find NS1 expression, and especially the ratio of NS1 to P-NS1, to differ in cells derived from breast tumors and normal breast tissue (Fig. 4) . In cultures of the latter (which are resistant to H-1 PV-induced CPE), NS1 was barely detectable at low MOI. At MOI 100 it was expressed, but seemed not to be correctly processed, since its phosphorylated (active) form was either absent or present at a much lower level than either NS1 or NS1-P in sensitive cultures, even when corresponding blots were produced 48 h after inoculation of H-1 PV at MOI 1.
NS-1 expression is under the control of the parvoviral promoter P4, the activation of which seems to depend on cell factors restricted to the S phase [19, 32] . Anouja et al. [33] have shown with a vector driving inducible, P4-independent NS-1 expression that only the nonphosphorylated form is expressed during the G 1 /S transition. This suggests that NS-1 phosphorylation also depends on cell factors available during the S phase [33] , hence the enhanced parvovirus activation observed in actively cycling cells. In our study, the tumors from which H-1 PVsensitive cultures were derived showed higher mitotic grades than expected for normal breast tissue (not measured in the normal tissue samples we examined). This might explain the better production and phosphorylation of NS1 in tumor-derived cultures.
In conclusion, our study using an in vitro assay to estimate the effect of H-1 PV on cells derived from patients' tumor tissue constitutes a first validation step toward proof-of-concept that H-1 PV may be an effective viral anti-cancer agent. We confirm here what has been shown so far mostly with tumor cell lines, since up to 67% of the cultures successfully derived from breast tumors (such cultures are more representative of the heterogenic nature of patients' tumors) were sensitive to H-1 PVinduced CPE depending on the doses of virus assayed.
Our study also indicates that cells derived from tumors with a high mitotic grade (actively cycling cells), and more particularly those showing lower levels of differentiation (identified by higher Nottingham combined histologic grades; P = 0.03), are most sensitive to H-1 PV-induced CPE. Patients with such tumors could be given priority for inclusion in a phase I clinical study based on the use of H-1 PV.
Our study confirms H-1 PV as a serious candidate for use in viral anticancer therapy, especially if it is associated with standard chemotherapy or radiotherapy [6, 34] .
